Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
September 1, 2025

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) (the "Company") received a notice from the National Medical Products Administration (the "NMPA"). The NMPA conditionally approves the Company's self-developed Class 1 innovative drug, Zeprumetostat Tablets (SHR2554 Tablets), for marketing. The drug is indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) who have received at least one prior line of systemic therapy. Zeprumetostat Tablets are the first domestically developed EZH2 inhibitor in China. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Common name of drug: Zeprumetostat Tablets

Dosage Form: Tablets

Specification: 50mg

Registered Category: Class 1 chemical drug

Application Number: CXHS2400102

Prescription/Non-prescription Drug: Prescription Drug

Approved indication: The drug is indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL) who have received at least one

prior line of systemic therapy.

II. Other Information of the Drug

Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous and aggressive malignant tumors of the lymphatic system. Among patients with non-Hodgkin's lymphoma in China, PTCL accounts for approximately 25%–30% [1], which is significantly higher than that in Western countries. Moreover, the median age at onset is 52 years, indicating relatively younger prevalence[2]. The clinical treatment of PTCL is highly challenging, as most patients relapse or become refractory after initial treatment [3]. A recent large-scale real-world study involving over one thousand Chinese patients showed that once patients entered second-line therapy, the median progression-free survival (PFS) decreased sharply from 30.5 months in first-line treatment to 5.2 months, highlighting the lack of effective subsequent treatment options and the limited chance of survival for patients with R/R PTCL [2].

Zeprumetostat Tablets are an innovative, effective, and selective oral EZH2 inhibitor developed by the Company. In January 2020, the U.S. Food and Drug Administration approved the oral EZH2 inhibitor Tazverik (tazemetostat) developed by Epizyme for marketing. In August 2021, HUTCHMED obtained the rights from Epizyme for the development and commercialization of tazemetostat in Greater China, and it was approved for use in June 2022 in the Hainan Boao Pilot Zone in China. In September 2022, the EZH1/2 inhibitor Ezharmia (valemetostat tosilate) developed by Daiichi Sankyo was approved for marketing in Japan. According to the EvaluatePharma database, global sales of Tazverik in 2024 totaled approximately USD 51.0 million. To date, a total of approximately RMB 213 million has been invested in the research and development of the SHR2554 Tablet-related projects.

III. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

September 1, 2025

[1] SUN J, YANG Q, LU Z, et al. Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classification [J]. Am J Clin Pathol, 2012, 138(3): 429-34.

[2] HUANG L, YANG Y, ZHAO Z, et al. Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study [J]. Discov Oncol, 2025, 16(1): 1252.

[3] LUAN Y, LI X, LUAN Y, et al. Therapeutic challenges in peripheral T-cell lymphoma [J]. Mol Cancer, 2024, 23(1):2.